LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.
Fair value with moderate growth potential.
Share Price & News
How has LivaNova's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LIA's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: LIA underperformed the German Medical Equipment industry which returned 22.4% over the past year.
Return vs Market: LIA underperformed the German Market which returned 6.5% over the past year.
Price Volatility Vs. Market
How volatile is LivaNova's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is LivaNova undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LIA (€61) is trading below our estimate of fair value (€222.09)
Significantly Below Fair Value: LIA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LIA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: LIA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LIA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LIA is good value based on its PB Ratio (2x) compared to the DE Medical Equipment industry average (5.3x).
How is LivaNova forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LIA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: LIA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LIA's is expected to become profitable in the next 3 years.
Revenue vs Market: LIA's revenue (4.9% per year) is forecast to grow slower than the German market (5.1% per year).
High Growth Revenue: LIA's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LIA's Return on Equity is forecast to be low in 3 years time (10.3%).
How has LivaNova performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LIA is currently unprofitable.
Growing Profit Margin: LIA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LIA is unprofitable, and losses have increased over the past 5 years at a rate of -54.3% per year.
Accelerating Growth: Unable to compare LIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LIA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17%).
Return on Equity
High ROE: LIA has a negative Return on Equity (-14.82%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is LivaNova's financial position?
Financial Position Analysis
Short Term Liabilities: LIA's short term assets ($546.8M) exceed its short term liabilities ($469.2M).
Long Term Liabilities: LIA's short term assets ($546.8M) exceed its long term liabilities ($545.5M).
Debt to Equity History and Analysis
Debt Level: LIA's debt to equity ratio (22.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if LIA's debt to equity ratio has reduced over the past 5 years.
Inventory Level: LIA has a low level of unsold assets or inventory.
Debt Coverage by Assets: LIA's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LIA has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: LIA has been profitable on average in the past, therefore cash runway is not a concern.
What is LivaNova's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate LIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LIA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LIA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LIA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LIA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Damien McDonald (54yo)
Mr. Damien McDonald is the Chief Executive Officer and an Executive Director of LivaNova PLC. since January 1, 2017. Mr. McDonald served as Chief Operating Officer of LivaNova from October 3, 2016 through ...
CEO Compensation Analysis
Compensation vs Market: Damien's total compensation ($USD7.11M) is above average for companies of similar size in the German market ($USD2.69M).
Compensation vs Earnings: Damien's compensation has increased whilst the company is unprofitable.
|CEO & Director||3.1yrs||US$7.11m||0.13% $3.7m|
|Chief Financial Officer||2.8yrs||US$2.97m||0.033% $932.0k|
|Chief Accounting Officer||3.6yrs||US$885.49k||0.0049% $135.6k|
|General Counsel & Senior VP||2.7yrs||US$1.62m||0.0034% $96.0k|
|Vice President of Investor Relations||0yrs||no data||no data|
|Director of Corporate Communications||0yrs||no data||no data|
|Senior Vice President of Corporate Development||2.1yrs||no data||no data|
|Chief Human Resources Officer||0.9yrs||no data||no data|
|Senior Vice President of Global Market Access||4.3yrs||no data||no data|
|Senior Vice President of Clinical||0yrs||no data||no data|
Experienced Management: LIA's management team is considered experienced (2.8 years average tenure).
|CEO & Director||3.1yrs||US$7.11m||0.13% $3.7m|
|Independent Director||13.3yrs||US$256.00k||0.0031% $87.6k|
|Independent Director||13.1yrs||US$240.00k||0.038% $1.1m|
|Independent Director||1.7yrs||US$173.45k||0.0033% $90.9k|
|Independent Director||4.3yrs||US$235.00k||0.0087% $243.8k|
|Independent Director||13.1yrs||US$243.00k||0.020% $551.5k|
|Independent Director||0.7yrs||no data||no data|
|Non-Executive Director||3.6yrs||US$235.00k||0.0062% $172.7k|
|Independent Director||4.3yrs||US$243.00k||0.0031% $87.6k|
Experienced Board: LIA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LivaNova PLC's company bio, employee growth, exchange listings and data sources
- Name: LivaNova PLC
- Ticker: LIA
- Exchange: DB
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.035b
- Listing Market Cap: US$2.790b
- Shares outstanding: 48.40m
- Website: https://www.livanova.com
Number of Employees
- LivaNova PLC
- 20 Eastbourne Terrace
- Greater London
- W2 6LG
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LIVN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Feb 1993|
|LIA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 1993|
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/26 23:28|
|End of Day Share Price||2020/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.